UBS O'Connor’s Procept Biorobotics PRCT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-25,226
Closed -$1.45M 412
2025
Q2
$1.45M Sell
25,226
-2,774
-10% -$157K 0.04% 181
2025
Q1
$1.63M Buy
+28,000
New +$1.91M 0.04% 142
2024
Q2
Sell
-13,217
Closed -$653K 622
2024
Q1
$653K Sell
13,217
-6,500
-33% -$309K 0.02% 315
2023
Q4
$826K Sell
19,717
-15,399
-44% -$524K 0.03% 297
2023
Q3
$1.15M Sell
35,116
-16,000
-31% -$545K 0.02% 315
2023
Q2
$1.81M Buy
51,116
+9,173
+22% +$303K 0.04% 318
2023
Q1
$1.19M Buy
41,943
+30,069
+253% +$1.06M 0.03% 389
2022
Q4
$493K Buy
+11,874
New +$510K 0.01% 621

Other funds holding PRCT

UBS O'Connor's PRCT Position: Q3 2025 in Review

UBS O'Connor sold out of Procept Biorobotics (PRCT) in Q3 2025, closing a stake of 25,226 shares — an estimated $1.45M sold.

UBS O'Connor first reported a position in PRCT in Q4 2022 and held it in 8 quarters. The position peaked at $1.81M in Q2 2023. 242 funds tracked by Wall St. Rank hold PRCT as of Q3 2025.

  • UBS O'Connor reported no remaining Procept Biorobotics position as of Q3 2025 after selling out during the quarter.
  • UBS O'Connor sold 25,226 Procept Biorobotics shares in Q3 2025, an estimated $1.45M.
  • UBS O'Connor first reported a position in Procept Biorobotics in Q4 2022 and held it in 8 quarters.
  • UBS O'Connor's Procept Biorobotics position peaked at $1.81M in Q2 2023.
  • 242 funds tracked by Wall St. Rank held Procept Biorobotics as of Q3 2025.

Based on UBS O'Connor's 13F filing for Q3 2025, filed 14 Nov 2025.